Study S001671

A PHASE 1, OPEN-LABEL, FIXED-SEQUENCE STUDY TO EVALUATE THE PHARMACOKINETIC INTERACTIONS BETWEEN PF-07976016 AND PF-06882961 IN OTHERWISE HEALTHY ADULT PARTICIPANTS WITH OVERWEIGHT OR OBESITY

ClinicalTrials.gov record

Registration

Registration: NCT06910839
Study type: INTERVENTIONAL
Phase: PHASE1
Masking: NONE
Status: TERMINATED
Enrollment: 21
Start: 2025-03-13
Primary completion: 2025-05-01
Lead sponsor: Pfizer
Conditions: Overweight; Obesity
Interventions: DRUG:PF-07976016; DRUG:PF-06882961
Results posted: FALSE
Individual participant data sharing: NO

Registered primary outcomes

Steady state area under the concentration-time profile for PF-07976016 [From 0 Hours to 24 Hours following steady-state dose]
Steady state maximum observed concentration (Cmax) for PF-07976016 [From 0 Hours to 24 Hours following steady-state dose]
Steady state area under the concentration-time profile danuglipron [From 0 Hours to 24 Hours following steady-state dose]
Steady state maximum observed concentration (Cmax) for danuglipron [From 0 Hours to 24 Hours following steady-state dose]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.